Science Advisory Committee on Pest Control Products (SAC-PCP) - Meeting Summary

Inaugural meeting, Friday July 8th, 2022, 1:00 to 6:00 pm EST

Virtual Meeting via Zoom

List of Participants

SAC-PCP Members

Dr. Valérie Langlois (co-chair)
Dr. Bruce Lanphear (co-chair)
Dr. Stéphane Bayen
Dr. Kyle Bobiwash
Dr. Eric Liberda
Dr. Christy Morrissey
Dr. Sean Prager
Dr. Xianming Zhang

Regrets

Dr. Maricor Arlos

Pest Management Regulatory Agency (PMRA) Executives

Peter Brander
Manon Bombardier

Secretariat

Shifawn O’Hara
Shannon Seguin
Stephanie Watson

PMRA presenters

Katie Calp
Martha Cunningham
Gillian Dawson
Lilian de Luna
Seynabou Diagne
Monika Engel
Bonnie MacLeod
Regi Mathew

Summary

Welcome and Introductory Remarks

Roundtable Introductions, Co-chairs Address and Review of Affiliations

Terms of Reference

Orientation

Charge Question

“From a scientific point of view, are proposed eligibility criteria 1 and 2 sufficient to meet the goals of the authorization proposal?”

To be considered for authorization, the products must meet all of the following criteria:

  1. With respect to health effects, the pest control productFootnote 1 or any of its derivatives, as the case may be, is not or does not contain a substance that:
    1. is chronically toxic under its intended use;
    2. is genotoxic, carcinogenic, neurotoxic or immunotoxic;
    3. causes reproductive or developmental effects; or
    4. bioaccumulates; and
  2. With respect to environmental effects, the pest control product2 or any of its derivatives, as the case may be, is not or does not contain a substance that:
    1. is chronically toxic under its intended use;
    2. causes reproductive or developmental effects;
    3. is persistent or, if persistent, is not toxic to human health or the environment under its intended use; or
    4. bioaccumulates; and
  3. The active ingredient or the product is available to the public for non-pesticidal uses.

Closing remarks

Footnotes

Footnote 1

A pest control product includes an active ingredient, a formulated (end-use) product, or a prescribed product, in accordance with the definition in section 2(1) of the PCPA.

Return to footnote 1 referrer

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: